Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC, Cardozo M, Houze J, Li Y, Lucas B, Paras NA, Wang X, Taygerly JP, Vimolratana M, Zancanella M, Zhu L, Cajulis E, Osgood T, Sun J, Damon L, Egan RK, Greninger P, McClanaghan JD, Gong J, Moujalled D, Pomilio G, Beltran P, Benes CH, Roberts AW, Huang DC, Wei A, Canon J, Coxon A, Hughes PE.

Cancer Discov. 2018 Dec;8(12):1582-1597. doi: 10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25. Erratum in: Cancer Discov. 2019 Jul;9(7):980.


MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.

Caenepeel S, Cooke K, Wadsworth S, Huang G, Robert L, Moreno BH, Parisi G, Cajulis E, Kendall R, Beltran P, Ribas A, Coxon A, Hughes PE.

Oncotarget. 2017 Mar 14;8(11):17795-17809. doi: 10.18632/oncotarget.14855.


Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE.

Clin Cancer Res. 2014 Jun 1;20(11):2947-58. doi: 10.1158/1078-0432.CCR-13-3448. Epub 2014 Apr 11.


IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.

Moody G, Beltran PJ, Mitchell P, Cajulis E, Chung YA, Hwang D, Kendall R, Radinsky R, Cohen P, Calzone FJ.

J Endocrinol. 2014 Mar 17;221(1):145-55. doi: 10.1530/JOE-13-0306. Print 2014 Apr.


Epitope-specific mechanisms of IGF1R inhibition by ganitumab.

Calzone FJ, Cajulis E, Chung YA, Tsai MM, Mitchell P, Lu J, Chen C, Sun J, Radinsky R, Kendall R, Beltran PJ.

PLoS One. 2013;8(2):e55135. doi: 10.1371/journal.pone.0055135. Epub 2013 Feb 1.


Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.

Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ.

J Pharmacol Exp Ther. 2011 Jun;337(3):644-54. doi: 10.1124/jpet.110.178400. Epub 2011 Mar 8.


AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.

Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ.

Mol Cancer Ther. 2009 May;8(5):1095-105. doi: 10.1158/1535-7163.MCT-08-1171. Epub 2009 Apr 14.


HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.

Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ.

Breast Cancer Res. 2005;7(6):R1058-79. Epub 2005 Nov 8.


Psychoneuroimmunology in oral biology and medicine: the model of oral lichen planus.

Prolo P, Chiappelli F, Cajulis E, Bauer J, Spackman S, Romeo H, Carrozzo M, Gandolfo S, Christensen R.

Ann N Y Acad Sci. 2002 Jun;966:429-40.


Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b.

Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ, Calzone FJ.

Oncogene. 1997 Jan 9;14(1):1-16.


Differential usage of the T cell receptor repertoire for allorecognition of heart, liver, and kidney grafts.

Shirwan H, Cajulis E, Makowka L, Cramer DV.

Transplantation. 1995 Jun 27;59(12):1709-14.


The synergism of brequinar sodium and cyclosporine used in combination to prevent cardiac allograft rejection in the rat.

Cosenza CA, Cramer DV, Eiras-Hreha G, Cajulis E, Wang HK, Makowka L.

Transplantation. 1993 Sep;56(3):667-72.


Individual and species differences in the in vitro sensitivity to brequinar sodium.

Eiras-Hreha G, Cramer DV, Cajulis E, Hill D, Frankland M, Hough K, Mills L, Nicholson B, Chapman F, Jaffee B, et al.

Transplant Proc. 1993 Jun;25(3 Suppl 2):61-4. No abstract available.


Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection.

Cosenza CA, Cramer DV, Eiras-Hreha G, Cajulis E, Wang HK, Makowka L.

Transplant Proc. 1993 Jun;25(3 Suppl 2):57-8. No abstract available.


Use of brequinar sodium for preventing cardiac allograft rejection in primates.

Makowka L, Tixier D, Chaux A, Hill D, O'Neill P, Eiras-Hreha G, Wu GD, Cunneen S, Cajulis E, Zajac I, et al.

Transplant Proc. 1993 Jun;25(3 Suppl 2):48-53. No abstract available.


Brequinar sodium: monitoring immunosuppressive activity.

Eiras-Hreha G, Cramer DV, Cosenza C, Chapman FA, Mills L, Cajulis E, Hill D, Jones E, Zajac I, Jaffee B, et al.

Transplant Proc. 1993 Jun;25(3 Suppl 2):32-6. Review.


Correlation of the in vitro and in vivo immunosuppressive activity of brequinar sodium.

Eiras-Hreha G, Cramer DV, Cajulis E, Cosenza C, Mills L, Hough K, Frankland M, Chapman F, Wang H, Zajac I, et al.

Transplant Proc. 1993 Feb;25(1 Pt 1):708-9. No abstract available.


Lymphocytic subsets and histopathologic changes associated with the development of heart transplant arteriosclerosis.

Cramer DV, Wu GD, Chapman FA, Cajulis E, Wang HK, Makowka L.

J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 1):458-66.


A comparison of lymphocytic subsets participating in concordant cardiac xenograft and acute cardiac allograft rejection.

Cramer DV, Wu GD, Chapman FA, Wang HK, Cajulis E, Makowka L.

Transplant Proc. 1992 Apr;24(2):533-4. No abstract available.


FK 506 inhibits the development of transplant arteriosclerosis.

Wu GD, Cramer DV, Chapman FA, Cajulis E, Wang HK, Starzl TE, Makowka L.

Transplant Proc. 1991 Dec;23(6):3272-4. No abstract available.

Supplemental Content

Loading ...
Support Center